The bench to bedside journey of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophy

AI Summary

This article likely discusses the development of tricyclo-DNA antisense oligonucleotides for the treatment of Duchenne muscular dystrophy. The term "bench to bedside" suggests a translation of scientific research from the laboratory setting to clinical applications. Tricyclo-DNA refers to a specific type of antisense oligonucleotide structure. The potential outcomes may include advancements in treating Duchenne muscular dystrophy, a genetic disorder characterized by muscle weakness. This research is significant for its potential impact on patients with this debilitating condition.